<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author><author><style face="normal" font="default" size="100%">Gargalianos, P</style></author><author><style face="normal" font="default" size="100%">Kiosses, V.</style></author><author><style face="normal" font="default" size="100%">Lazanas, M</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Anastassopoulou, C.</style></author><author><style face="normal" font="default" size="100%">Vigklis, V.</style></author><author><style face="normal" font="default" size="100%">Sambatakou, H</style></author><author><style face="normal" font="default" size="100%">Botsi, C.</style></author><author><style face="normal" font="default" size="100%">Paraskevis, D</style></author><author><style face="normal" font="default" size="100%">Stalgis, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication</style></title><secondary-title><style face="normal" font="default" size="100%">J Interferon Cytokine ResJ Interferon Cytokine ResJ Interferon Cytokine Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine Research</style></alt-title><short-title><style face="normal" font="default" size="100%">Journal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine ResearchJournal of interferon &amp; cytokine research : the official journal of the International Society for Interferon and Cytokine Res</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anti-HIV Agents/administration &amp; dosage/adverse effects/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiretroviral Therapy, Highly Active</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Infections/*drug therapy/immunology/virology</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV-1/*drug effects/genetics/isolation &amp; purification</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon-alpha/administration &amp; dosage/adverse effects/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Kinetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Lymphocyte Count</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Viral/analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Load</style></keyword><keyword><style  face="normal" font="default" size="100%">Virus Replication/*drug effects</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">21</style></volume><pages><style face="normal" font="default" size="100%">861-9</style></pages><isbn><style face="normal" font="default" size="100%">1079-9907 (Print)1079-9907 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">To evaluate the safety and antiviral action of interferon-alpha (IFN-alpha) in HIV-1 infection, we undertook a proof of concept study in 27 treatment-naive patients. Eligible patients comprised two groups: the IFN-alphaT group (n = 17), which received 5 MIU IFN-alpha s.c. daily for 32 consecutive days, and the IFN-alphaNT group (n = 10), which did not receive IFN-alpha prior to highly active antiretroviral therapy (HAART), which was commenced on day 28 in both groups. IFN-alphaTreatment was well tolerated in 14 of the 17 patients of the IFN-alphaT group who completed the study. The mean HIV RNA reduction in the IFN-alphaT group on day 14 was 1.1 log(10). Viral load suppression was inversely associated with baseline viral load (p = 0.031). Four weeks after initiation of HAART, IFN-alphaT and IFN-alphaNT group patients had 2.40 and 1.82 log(10) HIV RNA reduction from baseline, respectively (p &lt; 0.001). There was no evidence of cross-resistance with existing antiretrovirals in patients with HIV-RNA rebound after initial plasma viral load decline &gt; or = 1 log(10) during IFN-alpha monotherapy. Thus, low daily IFN-alpha exhibits potent anti-HIV-1 activity in vivo without serious adverse effects. These properties render IFN-alpha an attractive candidate for further assessment as a constituent of HAART.</style></abstract><accession-num><style face="normal" font="default" size="100%">11710999</style></accession-num><notes><style face="normal" font="default" size="100%">Hatzakis, AGargalianos, PKiosses, VLazanas, MSypsa, VAnastassopoulou, CVigklis, VSambatakou, HBotsi, CParaskevis, DStalgis, CengClinical TrialMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov't2001/11/17 10:00J Interferon Cytokine Res. 2001 Oct;21(10):861-9. doi: 10.1089/107999001753238114.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Hygiene and Epidemiology, Athens University Medical School, Athens, Greece. ahatzak@cc.uoa.gr</style></auth-address></record></records></xml>